The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Lundberg, M.D, recommended that third-party payers and the public should question paying for this procedure "until or unless additional honest experimentation demonstrates an actual effect." There is no good medical evidence for the effectiveness of therapeutic touch. A Cochrane systematic review, first published in 2004, found "[t]here is no robust evidence that TT promotes healing of acute wounds", but in 2016, the authors retracted it after the validity of the reviewed studies was questioned. The American Cancer Society notes, "Available scientific evidence does not support any claims that TT can cure cancer or other diseases."
Clothing, sportswear and accessories: polyester and PVC clothing, spandex, sport shoes, wetsuits, footballs and billiard balls, skis and snowboards, rackets, parachutes, sails, tents and shelters. Electronic and photonic technologies: organic field effect transistors (OFET), light emitting diodes (OLED) and solar cells, television components, compact discs (CD), photoresists, holography. Packaging and containers: films, bottles, food packaging, barrels. Insulation: electrical and thermal insulation, spray foams. Construction and structural applications: garden furniture, PVC windows, flooring, sealing, pipes. Paints, glues and lubricants: varnish, adhesives, dispersants, anti-graffiti coatings, antifouling coatings, non-stick surfaces, lubricants. Car parts: tires, bumpers, windshields, windscreen wipers, fuel tanks, car seats. Household items: buckets, kitchenware, toys (e.g., construction sets and Rubik's Cube). Medical applications: blood bag, syringes, rubber gloves, surgical suture, contact lenses, prosthesis, controlled drug delivery and release, matrices for cell growth. Personal hygiene and healthcare: diapers using superabsorbent polymers, toothbrushes, cosmetics, shampoo, condoms. Security: personal protective equipment, bulletproof vests, space suits, ropes. Separation technologies: synthetic membranes, fuel cell membranes, filtration, ion-exchange resins. Money: polymer banknotes and payment cards. 3D printing.
==== White Belizeans ==== Whites in Belize form around 4.8% of the population. A minority of less than one percent is from Ireland, the United Kingdom, the United States, Canada, Lebanon, and other countries brought to assist the country's development. Irish settlers and migrants and veterans from Louisiana and other Southern states established Confederate settlements in British Honduras and introduced commercial sugar cane production to the colony, establishing 11 settlements in the interior. The largest White group of almost four percent are the German speaking Mennonites who form a spectrum from very traditional and conservative groups like the Old Colony Mennonites and the Noah Hoover Mennonites to more modern groups like the Kleine Gemeinde, the Church of God in Christ, Mennonite (Holdeman Mennonites) and groups belonging to the Evangelical Mennonite Mission Conference.
=== Senses === As with other varanids, Komodo dragons have only a single ear bone, the stapes, for transferring vibrations from the tympanic membrane to the cochlea. This arrangement means they are likely restricted to sounds in the 400 to 2,000 hertz range, compared to humans who hear between 20 and 20,000 hertz. They were formerly thought to be deaf when a study reported no agitation in wild Komodo dragons in response to whispers, raised voices, or shouts. This was disputed when London Zoo employee Joan Procter trained a captive specimen to come out to feed at the sound of her voice, even when she could not be seen.
== Academic career == Heffernan earned a Bachelor of Science with Honours from the University of Otago. She worked at New Zealand's National Health Institute and the Institute of Environmental Science and Research (ESR), a Crown Research Institute. Heffernan's research involved the development of cold chain standards, which are important for the safe management and storage of vaccines. She also carried out surveillance for infectious diseases, allowing the rate of spread of antimicrobial resistance to be slowed. Heffernan's research was the basis for vaccine programmes against haemophilus influenzae type b, pneumococcus and meningococcus. Heffernan was a member a number of national committees, including the National Antimicrobial Committee, the Ministry for Primary Industries' Technical Advisory Group, and the Ministry of Health's Pneumococcal Surveillance Advisory Group. She spoke about New Zealand's place in the 'global antimicrobial crisis' at the One Health symposium in 2017. She also represented New Zealand at regional meetings in the Pacific, and at the World Health Organization's workshop on Antimicrobial Resistance Surveillance.
Sources: en.wikipedia.org
===== SeV stimulation of dendritic cells ===== UV-inactivated SeV can cause dendritic cells (DCs) to maturate and to infiltrate a tumor. Ex vivo infection of DCs with recombinant non-transmissible SeV induces maturation and activation of DCs within 60 minutes. When activated DCs that carry non-transmissible variants of SeV are administered, survival of animals injected with melanoma, colorectal cancer, squamous cell carcinoma, hepatic cancer, neuroblastoma, and prostate cancer is significantly improved. It has been shown that the administration of such DCs prior to tumor cell injection prevents metastasis of neuroblastoma and prostate adenocarcinoma to the lungs. The enzymatic removal of sialic acids from the surface of dendritic cells by sialidase significantly promote the antigen-induced activation of naive T cells, while concurrently enhancing the resurgence of effector T cells. It is plausible that sialidase from Sendai virus (SeV) could execute this function. The removal not only improves antigen cross-presentation but boosts anti-tumor immune responses as well. Dendritic cells with reduced sialylation form higher avidity interactions with CD8+ T cells.
The study of pathology, including the detailed examination of the body, dissection and inquiry into specific maladies, dates back to antiquity. Rudimentary understanding of many conditions was present in most early societies and is attested to in the records of the earliest historical societies, including those of the Middle East, India, and China. By the Hellenic period of ancient Greece, a concerted causal study of disease was underway (see Medicine in ancient Greece), with many notable early physicians (such as Hippocrates, for whom the modern Hippocratic Oath is named) having developed methods of diagnosis and prognosis for a number of diseases. The medical practices of the Romans and those of the Byzantines continued from these Greek roots, but, as with many areas of scientific inquiry, growth in understanding of medicine stagnated somewhat after the Classical Era, but continued to slowly develop throughout numerous cultures. Notably, many advances were made in the medieval era of Islam (see Medicine in medieval Islam), during which numerous texts of complex pathologies were developed, also based on the Greek tradition. Even so, growth in complex understanding of disease mostly languished until knowledge and experimentation again began to proliferate in the Renaissance, Enlightenment, and Baroque eras, following the resurgence of the empirical method at new centers of scholarship.
Electric spark ionization is used to produce gas phase ions from a solid sample. When incorporated with a mass spectrometer the complete instrument is referred to as a spark ionization mass spectrometer or as a spark source mass spectrometer (SSMS). A closed drift ion source uses a radial magnetic field in an annular cavity in order to confine electrons for ionizing a gas. They are used for ion implantation and for space propulsion (Hall-effect thrusters).
=== Pharmacokinetics === Migalastat is almost completely absorbed from the gut; taking the drug together with food decreases its absorption by about 40%. Total bioavailability is about 75% when taken without food. The substance is not bound to blood plasma proteins. Only a small fraction of a migalastat dose is metabolized, mainly to three dehydrogenated O-glucuronides (4% of the dose) and a number of unspecified metabolites (10%). The drug is mainly eliminated via the urine (77%) and to a smaller extent via the faeces (20%). Practically all of the metabolites are excreted in the urine. Elimination half-life is three to five hours after a single dose.
The adrenal glands are located above the kidneys in humans and in front of the kidneys in other animals. The adrenal glands produce a variety of hormones including adrenaline and the steroids aldosterone cortisol and Dehydroepiandrosterone sulfate (DHEA). Adrenaline increases blood pressure, heart rate, and metabolism in reaction to stress, the aldosterone controls the body's salt and water balance, the cortisol plays a role in stress response and the dehydroepiandrosterone sulfate (DHEA) produces aids in production of body odor and growth of body hair during puberty.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.